Company: SCLXW
Filing Date: 2025-08-21
Form Type: 424B3
Source: 0001193125-25-184627
Chunk: 20

Company: Scilex Holding Co
Filing Date: 2025-08-21
Form: 424B3
Chunk 20
---
 other products; the ability of the combined company to grow and manage growth profitably and retain its key
employees; the amount of redemption requests made by Denali’s shareholders; the inability to obtain or maintain the listing or trading of the post-acquisition company’s securities on The Nasdaq Stock Market LLC or the over-the-counter markets, as applicable, following the Business Combination; and costs related to the Business Combination. There may be additional risks that Semnur and the
Company presently do not know or that Semnur or the Company currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide
Semnur’s, the Company’s and Denali’s expectations, plans or forecasts of future events and views as of the date of the communication. Semnur and the Company anticipate that subsequent events and developments will cause such
assessments to change. However, while Semnur and the Company may elect to update these forward-looking statements at some point in the future, each of Semnur and the Company specifically disclaim any obligation to do so. These forward-looking
statements should not be relied upon as representing Semnur’s or the Company’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these
forward-looking statements.

Page | 5

Contacts:

Investors and Media

Scilex Holding Company

960 San Antonio Road

Palo Alto, CA 94303

Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website:
www.scilexholding.com

# # #

SEMDEXA (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA
is planned.

ZTlido is a registered trademark owned by Scilex Pharmaceuticals Inc., a
wholly-owned subsidiary of Scilex Holding Company.

Gloperba is the subject of an exclusive,
transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB is a
registered trademark owned by Scilex Holding Company.

Scilex Bio is a trademark owned by
Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

2025 Scilex Holding Company All Rights Reserved.

Page | 6